Active Mix Cap Retreated Movers- Host Hotels and Resorts (NYSE:HST), Teva Pharmaceutical (NYSE:TEVA)

Host Hotels and Resorts Inc (NYSE:HST) reported that Edward Walter will step down from his executive positions and as a member of the company’s Board, effective December 31, 2016. James Risoleo, Executive Vice President and Managing Director of Investments, West Coast and Europe, will succeed Walter as President and CEO, effective January 1, 2017.

James Risoleo joined Host Hotels in 1996 as Senior Vice President for Acquisitions. He was elected Executive Vice President and Chief Investment Officer in 2000. In 2012, he became Managing Director of Host Hotels’ European business activities. In 2015, Risoleo also assumed leadership for all of the company’s West Coast Investment activities.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.14% to close at $37.05 with the total traded volume of 515236 shares. GlancyProngay& Murray LLP declared that a class action lawsuit has been filed on behalf of investors who purchased Teva Pharmaceuticals (NYSE:TEVA) securities between February 10, 2015 and November 3, 2016, inclusive.

Teva investors have until January 5, 2017 to file a lead plaintiff motion.According to the complaint filed in this lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times. The firm has institutional ownership of 57.20%, while insider ownership included 2.70%. Its price to sales ratio ended at 1.81. TEVA attains analyst recommendation of 2.10 with week performance of 4.91%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *